Sensus Healthcare, Inc. (SRTS) Tops Q4 EPS by 2c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Sensus Healthcare Fourth Quarter Financial Results Feature Record Revenue and Continued Double-digit Growth
February 14, 2019 4:02 PM ESTBOCA RATON, Fla., Feb. 14, 2019 /PRNewswire/ --Â Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces financial results for the three and 12 months ended December 31, 2018.
Highlights from the fourth quarter of 2018 include (all comparisons are with the fourth quarter of 2017, unless otherwise indicated):
Continued double-digit growth with revenues of $8.1 million, up 25% Net income of $0.1 million, or $0.01 per share, compared to $(0.4) million net loss, or $(0.03) per share Adjusted EBITDA, a non-GAAP financial measure, also turned positive... More